PF-04447943 (Synonyms: PF 04447943;PF04447943)

Kinase experiment:

PDE enzyme assays are carried out. PDE1A-C, PDE2A, PDE3A/B, PDE4A-D, PDE7A/B, PDE8A/B, PDE9A, PDE10A, and PDE11 are generated from full-length recombinant clones. PDE5 is isolated from human platelets, and PDE6 is isolated from bovine retina. PDE activity is measured by using a scintillation proximity assay (SPA). The effects of PDE inhibitors are investigated by assaying a fixed amount of enzyme and varying inhibitor concentrations in the presence of substrate concentrations of 1/3 Km values for each enzyme, so that the IC50 value approximates the Ki value. PF-4447943 is dissolved in 100% DMSO and diluted to the required concentrations in 15% DMSO water. The enzyme stocks are all thawed slowly and diluted in assay buffer containing 50 mM Tris-HCl (pH 7.5 at room temperature) and 1.3 mM MgCl2. In addition, the PDE1 assay buffers contain 2.8 mM CaCl2. The PDE1C assay also requires the addition of the activator calmodulin at a final assay concentration of 100 units/mL. Incubations are initiated by the addition of diluted enzyme to 384-well plates containing test drugs and radioligand (50 nM [3H]cGMP for PDE1, PDE2, PDE5, PDE6, PDE9, PDE10, and PDE11 and 20 nM [3H]cAMP for PDE3, PDE4, PDE7, and PDE8). The assays are incubated for 30 min at room temperature (60 min for PDE5 and PDE6). The reactions are stopped by the addition of phosphodiesterase SPA beads at a final assay concentration of 0.2 mg/well. PDE9 requires the extra addition of a high concentration (10 μM) of a potent PDE9 inhibitor before beads to stop the reaction completely. Activities of test compounds are assessed by measuring the amount of [3H]5′-GMP or [3H]5′-AMP produced from [3H]cGMP or [3H]cAMP radioligand, respectively. Levels of [3H]5′-GMP or [3H]5′-AMP binds to SPA beads are determined by paralux counting of the assay plates in a Microbeta Trilux Counter 10 h after bead addition. Nonspecific binding is determined by radioligand binding in the presence of a saturating concentration of a potent PDE inhibitor. The IC50 value of each test compound (concentration at which 50% inhibition of specific binding occurs) is calculated by nonlinear regression (curve fitting) of the concentration response[1].

Cell experiment:

The rhesus PDE9A2 construct is subcloned into a pcDNA3.3 TOPO vector and HEK 293 cells, stably transfected to constitutively express rhesus PDE9A2 and hNPR1, are incubated with PF-04447943 (30 μM to 1.5 nM) in assay media at a density of 10,000 cells/well, for 30 min at 37°C. Cyclic GMP formation is stimulated by incubation with 0.3 μM ANP (Atrial Natriuretic Peptide) for another 30 min at 37°C. Following incubation, cells are lysed with Antibody/Lysis buffer and ED Reagent for 1 h at room temperature. After a subsequent incubation with EA Reagent for 30 min at room temperature, followed by incubation with Substrate Reagent for 1 h at room temperature, cGMP concentrations are determined by measuring luminescence on the Envision Microplate Luminometer. The maximal inhibition (100% activity) in the cell based assay is determined using 30 μM PF-04447943 and 0% activity is defined by the DMSO control. PF-04447943 is titrated in quadruplicate, in a 10 point titration. Percentage inhibition is calculated using the maximal inhibition value and IC50 values are calculated from concentration response curves using Prism software[2].

Animal experiment:

Mice and Rats[2] For the mouse studies, male C57Bl/6J mice are administered PF-04447943 (3, 10, 30 mg/kg p.o.). For the rat studies rats (strain, weight range and supplier as described in the novel object recognition study below) are administered PF-04447943 10 mg/kg i.v. and p.o. At various times after administration the animals are anesthetized with isoflurane; blood samples are withdrawn via cardiac puncture and placed in EDTA tubes on ice. Plasma is separated and frozen at −70°C until assayed for drug concentration. The animals are decapitated, the brain is removed, then homogenized in 3 mL of water per gram of tissue and centrifuged for 15 min at 13,500 g. Sample analysis is conducted using an Acquity UPLC system coupled with a SCIEX API4000 Q-Trap mass spectrometer. Two μL of the sample extract is analyzed using an Acquity UPLC®BEH C18 column (1.7 μm particle size, 50×2.1 mm I.D.) operated at 60°C. The flow rate is 0.7 mL/min. A gradient mobile phase consisting of solvent A (20/80 Methanol/Water, 10 mM Ammonium Acetate) and solvent B (10 mM Ammonium Acetate in Methanol with 0.6 mL/L 10% acetic Acid) is used. The total run time for each sample is 1.2 min. PF-04447943 and the internal standard eluted at 0.61 and 0.67 min, respectively. PF-04447943 and the internal standard are monitored in the positive ion mode at the transition from m/z 396.2 to 203.1 and m/z 477.3 to 266.2, respectively. Quantification is performed using Analyst 1.4 based on duplicate standard curves.

References:

[1]. Kleiman RJ, et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther. 2012 May;341(2):396-409.
[2]. Hutson, P. H, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and